A Phase 4 interventional study of Tacrolimus and Tacrolimus immediate release in Kidney Transplantation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 30 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first year post-transplant.
This was an exploratory, two year (shortened to 1 year due to a stopping rule necessitated by the adaptive design), prospective, randomized, multi-center, open-label trial examining long-term kidney transplant outcomes through the use of an adaptive design and a two-part, composite surrogate endpoint. Specifically, it was designed to compare the effects of twice daily, immediate-release tacrolimus and once daily Astagraf XL on DSA formation and the development of a peripheral blood molecular profile indicating the presence of IA in de novo kidney transplant recipients during the first year following transplantation. For the purposes of this study, IA was defined as a positive molecular signature using a molecular assay in all participants.
Participants were screened prior to surgery and randomized 1:1 to receive immediate-release tacrolimus, administered twice daily, or Astagraf XL, as a component of a standard immunosuppression maintenance regimen also consisting of corticosteroids (if given per institutional protocol) and mycophenolate mofetil (MMF) (or Myfortic® equivalent). Investigators were encouraged to start participants on the randomized study treatment (immediate release tacrolimus or Astagraf XL) within 48 hours of transplantation (pre-transplant administration of study treatment was not allowed). However, if medically indicated per the treating physician's discretion, initiation of study treatment was delayed for up to seven days post-transplant.
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject must be either:
a. Of non- i. (defined as at least 1 year without any menses) prior to screening, or ii. Documented surgically sterile or status post-hysterectomy b. Or, if of childbearing potential, i. Agree not to try to become pregnant during the study and for 90 days after the final study drug administration ii. And have a negative serum or urine pregnancy test within 7 days prior to transplant procedure iii. And, if heterosexually active, agree to consistently use two forms of highly effective (at least one of which must be a barrier method) which includes consistent and correct usage of established oral contraception, established intrauterine device or intrauterine system, or barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository or vasectomy in the male partner, starting at screening and throughout the study period and for 90 days after the final study drug administration.
Exclusion Criteria:
Presence of current or historic pre-formed anti-Human Leukocyte Antigen (HLA) DSA against the current donor (evidence of pre-formed, non-donor HLA is not exclusionary) as defined by a subject meeting any of the following criteria*: a) positive virtual crossmatch, b) positive T- or B-cell crossmatch by National Institutes of Health (NIH) antiglobulin lymphocytotoxicity method** , c) .Positive T- or B-cell flow cytometry crossmatch defined by the Multiparameter flow cytometry (MFC) criteria used by the center's HLA lab for their local proficiency testing.,** d) An Mean Fluorescence Intensity (MFI) greater than or approaching 1000 using flow cytometry/Luminex-based, specific anti-HLA antibody testing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
Drug: Tacrolimus
Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
Drug: Tacrolimus immediate release
Oral Capsule
Also known as: Advagraf, FK506E, Astagraf XL
Oral Capsule
Also known as: FK506, Prograf, generic immediate release tacrolimus
Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching mean fluorescence intensity (MFI)=1000 at any time during the study. IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Were Positive, Negative or Indeterminate for dnDSA Occurrence
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study. Indeterminate was defined as MFI signal was \>1000 and DSA was suspected, but could not be confirmed due to inadequate donor typing. Participants whose samples for the test were not available were reported as unknown.
Time frame: From date of transplant until 1 year
Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants
Peak MFI of DSA positive participants was reported.
Time frame: From date of transplant until 1 year
Percentage of DSA Positive Participants With Weak, Moderate and Strong Antibody Strentgh
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.
Time frame: From date of transplant until 1 year
Percentage of DSA Positive Participants With DSA Persistence
DSA was regarded as persistent under the following conditions: (i) DSA was detected and remained above the threshold for positivity (MFI = 1000) for two consecutive or nonconsecutive measurements, or (ii) the new appearance of a DSA at the threshold for positivity when preceded by a DSA of a different specificity that had subsequently become non-detectable.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Were Positive or Negative for Complement Component 1, Q Subcomponent (C1q)-Binding DSA
Percentage of participants who were positive or negative for C1q-binding DSA were reported.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Were Positive or Negative for DSA Immunoglobulin G (IgG3) Isotype
Percentage of participants who were positive or negative for IgG3 isotype were reported.
Time frame: From date of transplant until 1 year
Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)
Percentage of DSA positive participants with HLA-DQ Class-II were reported.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit
IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
Time frame: From day 1 to day 365 visit
Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit
IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
Time frame: From day 30 to day 365 visit
Percentage of Participants With IA Persistence
IA was regarded as persistent under the following conditions: (i) IA was detected and remained above the threshold for positivity for two consecutive or non-consecutive measurements, or (ii) the new appearance of an IA at the threshold for positivity when preceded by an IA of a different specificity that had subsequently become non-detectable.
Time frame: From date of transplant until 1 year
Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy
TG was defined as chronic glomerulopathy (cg) \>0 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant with +2 months visit window.
Time frame: From date of transplant until month 14
Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy
MI was defined as glomerulitis (g) + peritubular capillaritis (ptc)\>=2 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant, with +2 months visit window.
Time frame: From date of transplant until month 14
Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy
IFTA and inflammation was defined as IFTA positive and inflammation positive (i \>0) on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year posttransplant, with +2 months visit window.
Time frame: From date of transplant until month 14
Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)
The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Time frame: At 1 year post transplant
Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2
The eGFR was calculated using the MDRD formula.
Time frame: At 1 year post transplant
Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2
The eGFR was calculated using the MDRD formula.
Time frame: At 1 year post transplant
Percentage of Participants With a Five-point Decline in eGFR
The eGFR was calculated using the MDRD formula.
Time frame: From 30 days post transplant until 1 year
eGFR at Day 30, Day 90, Day 180, Day 270 and Day 365
The eGFR was calculated using the MDRD formula.
Time frame: Day 30, day 90, day 180, day 270 and day 365
Percentage of Participants With Graft Loss
Graft loss was defined as re-transplantation, transplant nephrectomy, or a return to dialysis for at least a six week duration, or participants' death.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Died
Percentage of participants who died were reported.
Time frame: From date of transplant until 1 year
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)
Positivity was determined by local biopsy, central pathology, or reported adverse events.
Time frame: From date of transplant until 1 year
Percentage of Participants Who Were Lost to Follow-up
Percentage of participants who were lost to follow-up were reported.
Time frame: From date of transplant until 1 year
Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up
Percentage of participants with either graft loss, death, BPAR or lost to follow-up were reported.
Time frame: From date of transplant until 1 year
Percentage of Participants With Any Antibody-Mediated Rejection (ABMR)
Percentage of participants with ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. A positive assessment is defined as antibody mediated changes that are diagnosed as either acute ABMR or chronic active ABMR.
Time frame: From date of transplant until month 14
Percentage of Participants With Normal Biopsy Findings
Percentage of participants with normal biopsy findings were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With C4d Deposition Without Active Rejection
Percentage of participants with C4d deposition without active rejection were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Acute ABMR
Percentage of participants with acute ABMR were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Grade I, II and III Acute ABMR
Percentage of participants with grade I, II and III acute ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Acute ABMR was graded as Grade I: acute tubular necrosis-like -like minimal inflammation, Grade II: Capillary and or glomerular inflammation (ptc/g \>0) and/or thromboses, and Grade III: arterial - v3.
Time frame: From date of transplant until month 14
Percentage of Participants With Chronic ABMR
Percentage of participants with chronic ABMR were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Borderline Changes
Percentage of participants with borderline changes were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Acute T-cell Mediated Rejection (TCMR)
Percentage of participants with acute TCMR were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Chronic TCMR
Percentage of participants with chronic TCMR were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Grade I, II and III IFTA
Percentage of participants with Grade I, II and III IFTA were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. IFTA was graded as Grade I: mild interstitial fibrosis and tubular atrophy (\<25% of cortical area), Grade II: moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area), and Grade III: severe interstitial fibrosis and tubular atrophy/ loss (\>50% of cortical area).
Time frame: From date of transplant until month 14
Percentage of Participants With Any Additional Findings
Percentage of participants with any additional findings (other than Normal biopsy, borderline changes, acute and chronic ABMR, Grade I, II, and III ABMR, C4D deposition, acute and chronic TCMR, Grade I, II, and III TCMR, Grade I, II and III IFTA, acute tubular necrosis, interstitial nephritis, pyelonephritis, bk virus, calcineurin inhibitor toxicity, hemolytic uremic syndrome and recurrent disease) were reported.
Time frame: From date of transplant until month 14
Percentage of Participants With Glomerulitis (g) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No glomerulitis, Score 1= \<25% glomerulitis, Score 2= 25 to 75% glomerulitis and Score 3= \>75% glomerulitis.
Time frame: From date of transplant until month 14
Percentage of Participants With Tubulitis (t) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No mononuclear cells in tubules or single focus of tubulitis only, Score 1= Foci with 1 to 4 mononuclear cells/tubular cross section (or 10 tubular cells), Score 2= Foci with 5 to 10 mononuclear cells/tubular cross section (or 10 tubular cells) and Score 3= Foci with \>10 mononuclear cells/tubular cross section or the presence of ≥2 areas of tubular basement membrane destruction accompanied by i2/i3 inflammation and t2 elsewhere.
Time frame: From date of transplant until month 14
Percentage of Participants With Intimal Arteritis (v) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No arteritis, Score 1= Mild to moderate intimal arteritis in at least 1 arterial cross section, Score 2= Severe intimal arteritis with at least 25% luminal area lost in at least 1 arterial cross section and Score 3= Transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate in vessel.
Time frame: From date of transplant until month 14
Percentage of Participants With Mononuclear Cell Interstitial Inflammation (i) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No inflammation or in less than 10% of unscarred cortical parenchyma, Score 1= Inflammation in 10 to 25% of unscarred cortical parenchyma, Score 2= Inflammation in 26 to 50% of unscarred cortical parenchyma and Score 3= Inflammation in more than 50% of unscarred cortical parenchyma.
Time frame: From date of transplant until month 14
Percentage of Participants With Glomerular Basement Membrane Double Contours (cg) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No GBM double contours by light microscopy (LM) or electron microscopy (EM), Score 1= No GBM double contours by LM but GBM double contours (incomplete or circumferential) in at least 3 glomerular capillaries by EM or Double contours of the GBM in 1-25% of capillary loops in the most affected nonsclerotic glomerulus by LM , Score 2= Double contours affecting 26 to 50% of peripheral capillary loops in the most affected-glomerulus and Score 3= Double contours affecting more than 50% of peripheral capillary loops in the most affected-glomerulus.
Time frame: From date of transplant until month 14
Percentage of Participants With Tubular Atrophy (ct) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No tubular atrophy, Score 1= Tubular atrophy involving up to 25% of the area of cortical tubules, Score 2= Tubular atrophy involving 26 to 50% of the area of cortical tubules and Score 3= Tubular atrophy involving in \>50% of the area of cortical tubules.
Time frame: From date of transplant until month 14
Percentage of Participants With Interstitial Fibrosis (ci) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Interstitial fibrosis in up to 5% of cortical area, Score 1= Interstitial fibrosis in 6 to 25%of cortical area (mild interstitial fibrosis), Score 2= Interstitial fibrosis in 26 to 50% of cortical area (moderate interstitial fibrosis) and Score 3= Interstitial fibrosis in \>50% of cortical area (severe interstitial fibrosis).
Time frame: From date of transplant until month 14
Percentage of Participants With Vascular Fibrous Intimal Thickening (cv) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No chronic vascular changes, Score 1= Vascular narrowing of up to 25% luminal area by fibrointimal thickening, Score 2= Vascular narrowing of 26 to 50% luminal area by fibrointimal thickening and Score 3= Vascular narrowing of more than 50% luminal area by fibrointimal thickening.
Time frame: From date of transplant until month 14
Percentage of Participants With Arteriolar Hyalinosis (ah) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No periodic acid-Schiff (PAS)-positive hyaline arteriolar thickening, Score 1= Mild to moderate PAS-positive hyaline thickening in at least 1 arteriole, Score 2= Moderate to severe PAS-positive hyaline thickening in more than 1 arteriole and Score 3= Severe PAS-positive hyaline thickening in many arterioles.
Time frame: From date of transplant until month 14
Percentage of Participants With Peritubular Capillaritis (Ptc) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Maximum number of leukocytes \<3, Score 1= At least 1 leukocyte cell in ≥10% of cortical PTCs with 3-4 leukocytes in most severely involved PTC, Score 2= At least 1 leukocyte in ≥10% of cortical PTC with 5-10 leukocytes in most severely involved PTC and Score 3= At least 1 leukocyte in ≥10% of cortical PTC with \>10 leukocytes in most severely involved PTC.
Time frame: From date of transplant until month 14
Percentage of Participants With Mesangial Matrix Expansion (mm) Biopsy Score Assessed Using Banff Lesion Scores
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No more than mild mesangial matrix increase in any glomerulus, Score 1= At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli, Score 2= At least moderate mesangial matrix increase in 26% to 50% of nonsclerotic glomeruli and Score 3= At least moderate mesangial matrix increase in \>50% of nonsclerotic glomeruli.
Time frame: From date of transplant until month 14
Time to First Occurrence of DSA
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.
Time frame: From date of transplant until 1 year
Time to First Occurrence of HLA-DQ DSA
Time to first occurrence of HLA-DQ DSA was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of C1q-binding DSA
Time to first occurrence of C1q-binding DSA was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of DSA IgG3 Isotype
Time to first occurrence of DSA IgG3 isotype was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of IA
Time to first occurrence of IA was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of TG on Biopsy
Time to first occurrence of TG on biopsy was reported.
Time frame: From date of transplant until 1 year
Time to Occurrence of Death
Time to occurrence of death was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Local BPAR
Time to first occurrence of local BPAR was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Acute Forms of ABMR
Time to first occurrence of acute forms of ABMR was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Chronic Forms of ABMR
Time to first occurrence of chronic forms of ABMR was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Acute TCMR
Time to first occurrence of acute TCMR was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Chronic TCMR
Time to first occurrence of chronic TCMR was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of Borderline Changes
Time to first occurrence of borderline changes was reported.
Time frame: From date of transplant until 1 year
Time to First Occurrence of IFTA
Time to first occurrence of IFTA was reported.
Time frame: From date of transplant until 1 year
Percentage of Participants With Treatment-emergent Adverse Event(TEAEs), Related TEAEs, Treatment-emergent Serious Adverse Event (TESAEs), Related TESAEs, TEAEs Leading to Discontinuation of Study Treatment and TEAEs Leading to Death
A TEAE was defined as an Adverse Event (AE) observed on or after the day of starting the administration of the test drug/comparative drug.
Time frame: From first dose of study drug up to 7 days after last dose of study drug (up to 2 years)
| Milestone | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release Twice Daily (BID) |
|---|---|---|
| Started | 300 | 299 |
| Completed | 204 | 198 |
| Not completed | 96 | 101 |
| Withdrew: Adverse event | 48 | 40 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lack of efficacy | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 7 |
| Withdrew: Protocol violation | 20 | 23 |
| Withdrew: Withdrawal by subject | 4 | 8 |
| Withdrew: Randomized but never received studydrug | 12 | 12 |
| Withdrew: Miscellaneous | 5 | 6 |
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching mean fluorescence intensity (MFI)=1000 at any time during the study. IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence | 35.6 | 34.4 |
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study. Indeterminate was defined as MFI signal was \>1000 and DSA was suspected, but could not be confirmed due to inadequate donor typing. Participants whose samples for the test were not available were reported as unknown.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Positive | 5.5 | 4.3 |
| Negative | 90.5 | 92.8 |
| Indeterminate | 4 | 2.5 |
| Unknown | 0 | 0.4 |
Peak MFI of DSA positive participants was reported.
| fluorescence intensity unit | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants | 6119.21 (1320.0 to 29317.6) | 2727.99 (1066.0 to 19971.5) |
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Weak | 0 | 0 |
| Moderate | 73.3 | 83.3 |
| Strong | 26.7 | 16.7 |
DSA was regarded as persistent under the following conditions: (i) DSA was detected and remained above the threshold for positivity (MFI = 1000) for two consecutive or nonconsecutive measurements, or (ii) the new appearance of a DSA at the threshold for positivity when preceded by a DSA of a different specificity that had subsequently become non-detectable.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of DSA Positive Participants With DSA Persistence | 73.3 | 50 |
Percentage of participants who were positive or negative for C1q-binding DSA were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Positive | 1.8 | 0.4 |
| Negative | 98.2 | 99.6 |
Percentage of participants who were positive or negative for IgG3 isotype were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Positive | 0.7 | 1.1 |
| Negative | 99.3 | 98.9 |
Percentage of DSA positive participants with HLA-DQ Class-II were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ) | 40 | 25 |
IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit | 31.3 | 31.2 |
IA was considered either present or absent using the Trugraf™ v2.0 molecular assay. A negative designation (Trugraf TX Normal) was referred to as Immune Quiescence (IQ). Due to operating characteristics of the assay, a positive designation was considered evidence of IA in all participants.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit | 21.8 | 21.9 |
IA was regarded as persistent under the following conditions: (i) IA was detected and remained above the threshold for positivity for two consecutive or non-consecutive measurements, or (ii) the new appearance of an IA at the threshold for positivity when preceded by an IA of a different specificity that had subsequently become non-detectable.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With IA Persistence | 7.3 | 10 |
TG was defined as chronic glomerulopathy (cg) \>0 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant with +2 months visit window.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy | 6.5 | 6.6 |
MI was defined as glomerulitis (g) + peritubular capillaritis (ptc)\>=2 on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year post-transplant, with +2 months visit window.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy | 8.9 | 5.9 |
IFTA and inflammation was defined as IFTA positive and inflammation positive (i \>0) on centrally-interpreted institutional protocol biopsy or biopsy obtained for cause during the first year posttransplant, with +2 months visit window.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy | 26 | 16.9 |
The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2) | 1.5 | 1.8 |
The eGFR was calculated using the MDRD formula.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2 | 9.5 | 5.7 |
The eGFR was calculated using the MDRD formula.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2 | 25.5 | 19.7 |
The eGFR was calculated using the MDRD formula.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With a Five-point Decline in eGFR | 13.1 | 11.1 |
The eGFR was calculated using the MDRD formula.
| mL/min/1.73 m^2 | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Day 30 | 50.86 ± 17.27 | 52.72 ± 19.40 |
| Day 90 | 55.56 ± 16.00 | 57.10 ± 19.99 |
| Day 180 | 56.81 ± 15.84 | 58.33 ± 17.51 |
| Day 270 | 57.19 ± 16.84 | 59.04 ± 18.19 |
| Day 365 | 58.25 ± 16.51 | 60.94 ± 17.83 |
Graft loss was defined as re-transplantation, transplant nephrectomy, or a return to dialysis for at least a six week duration, or participants' death.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Graft Loss | 1.5 | 1.4 |
Percentage of participants who died were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants Who Died | 0.7 | 0.7 |
Positivity was determined by local biopsy, central pathology, or reported adverse events.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) | 7.6 | 8.2 |
Percentage of participants who were lost to follow-up were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants Who Were Lost to Follow-up | 0 | 0.7 |
Percentage of participants with either graft loss, death, BPAR or lost to follow-up were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up | 9.1 | 10.4 |
Percentage of participants with ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. A positive assessment is defined as antibody mediated changes that are diagnosed as either acute ABMR or chronic active ABMR.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Any Antibody-Mediated Rejection (ABMR) | 1.6 | 0.7 |
Percentage of participants with normal biopsy findings were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Normal Biopsy Findings | 6.5 | 4.4 |
Percentage of participants with C4d deposition without active rejection were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With C4d Deposition Without Active Rejection | 0.8 | 0.7 |
Percentage of participants with acute ABMR were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Acute ABMR | 1.6 | 0.7 |
Percentage of participants with grade I, II and III acute ABMR were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Acute ABMR was graded as Grade I: acute tubular necrosis-like -like minimal inflammation, Grade II: Capillary and or glomerular inflammation (ptc/g \>0) and/or thromboses, and Grade III: arterial - v3.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Grade I | 50 | 0 |
| Grade II | 50 | 100 |
| Grade III | 0 | 0 |
Percentage of participants with chronic ABMR were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Chronic ABMR | 0 | 0 |
Percentage of participants with borderline changes were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Borderline Changes | 14.6 | 14.7 |
Percentage of participants with acute TCMR were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Acute T-cell Mediated Rejection (TCMR) | 6.5 | 5.9 |
Percentage of participants with chronic TCMR were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Chronic TCMR | 25 | 12.5 |
Percentage of participants with Grade I, II and III IFTA were reported. Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. IFTA was graded as Grade I: mild interstitial fibrosis and tubular atrophy (\<25% of cortical area), Grade II: moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area), and Grade III: severe interstitial fibrosis and tubular atrophy/ loss (\>50% of cortical area).
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Grade I | 54.5 | 56.6 |
| Grade II | 18.7 | 15.4 |
| Grade III | 5.7 | 6.6 |
Percentage of participants with any additional findings (other than Normal biopsy, borderline changes, acute and chronic ABMR, Grade I, II, and III ABMR, C4D deposition, acute and chronic TCMR, Grade I, II, and III TCMR, Grade I, II and III IFTA, acute tubular necrosis, interstitial nephritis, pyelonephritis, bk virus, calcineurin inhibitor toxicity, hemolytic uremic syndrome and recurrent disease) were reported.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Percentage of Participants With Any Additional Findings | 29.3 | 34.6 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No glomerulitis, Score 1= \<25% glomerulitis, Score 2= 25 to 75% glomerulitis and Score 3= \>75% glomerulitis.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 89.4 | 90.4 |
| Banff Lesion Score 1 | 5.7 | 6.6 |
| Banff Lesion Score 2 | 4.1 | 1.5 |
| Banff Lesion Score 3 | 0 | 0 |
| Not able to score | 0.8 | 1.5 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No mononuclear cells in tubules or single focus of tubulitis only, Score 1= Foci with 1 to 4 mononuclear cells/tubular cross section (or 10 tubular cells), Score 2= Foci with 5 to 10 mononuclear cells/tubular cross section (or 10 tubular cells) and Score 3= Foci with \>10 mononuclear cells/tubular cross section or the presence of ≥2 areas of tubular basement membrane destruction accompanied by i2/i3 inflammation and t2 elsewhere.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 79.7 | 79.4 |
| Banff Lesion Score 1 | 16.3 | 15.4 |
| Banff Lesion Score 2 | 1.6 | 1.5 |
| Banff Lesion Score 3 | 1.6 | 2.9 |
| Not able to score | 0.8 | 0.7 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No arteritis, Score 1= Mild to moderate intimal arteritis in at least 1 arterial cross section, Score 2= Severe intimal arteritis with at least 25% luminal area lost in at least 1 arterial cross section and Score 3= Transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate in vessel.
| Percentage of Participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 93.5 | 94.9 |
| Banff Lesion Score 1 | 2.4 | 2.2 |
| Banff Lesion Score 2 | 2.4 | 0 |
| Banff Lesion Score 3 | 0 | 0 |
| Not able to score | 1.6 | 2.9 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No inflammation or in less than 10% of unscarred cortical parenchyma, Score 1= Inflammation in 10 to 25% of unscarred cortical parenchyma, Score 2= Inflammation in 26 to 50% of unscarred cortical parenchyma and Score 3= Inflammation in more than 50% of unscarred cortical parenchyma.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 68.3 | 76.5 |
| Banff Lesion Score 1 | 26.8 | 17.6 |
| Banff Lesion Score 2 | 4.1 | 2.2 |
| Banff Lesion Score 3 | 0 | 2.9 |
| Not able to score | 0.8 | 0.7 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No GBM double contours by light microscopy (LM) or electron microscopy (EM), Score 1= No GBM double contours by LM but GBM double contours (incomplete or circumferential) in at least 3 glomerular capillaries by EM or Double contours of the GBM in 1-25% of capillary loops in the most affected nonsclerotic glomerulus by LM , Score 2= Double contours affecting 26 to 50% of peripheral capillary loops in the most affected-glomerulus and Score 3= Double contours affecting more than 50% of peripheral capillary loops in the most affected-glomerulus.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 93.5 | 93.4 |
| Banff Lesion Score 1 | 5.7 | 3.7 |
| Banff Lesion Score 2 | 0 | 1.5 |
| Banff Lesion Score 3 | 0 | 0 |
| Not able to score | 0.8 | 1.5 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No tubular atrophy, Score 1= Tubular atrophy involving up to 25% of the area of cortical tubules, Score 2= Tubular atrophy involving 26 to 50% of the area of cortical tubules and Score 3= Tubular atrophy involving in \>50% of the area of cortical tubules.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 20.3 | 21.3 |
| Banff Lesion Score 1 | 53.7 | 55.9 |
| Banff Lesion Score 2 | 19.5 | 15.4 |
| Banff Lesion Score 3 | 5.7 | 6.6 |
| Not able to score | 0.8 | 0.7 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Interstitial fibrosis in up to 5% of cortical area, Score 1= Interstitial fibrosis in 6 to 25%of cortical area (mild interstitial fibrosis), Score 2= Interstitial fibrosis in 26 to 50% of cortical area (moderate interstitial fibrosis) and Score 3= Interstitial fibrosis in \>50% of cortical area (severe interstitial fibrosis).
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 21.1 | 20.6 |
| Banff Lesion Score 1 | 52.8 | 56.6 |
| Banff Lesion Score 2 | 19.5 | 15.4 |
| Banff Lesion Score 3 | 5.7 | 6.6 |
| Not able to score | 0.8 | 0.7 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No chronic vascular changes, Score 1= Vascular narrowing of up to 25% luminal area by fibrointimal thickening, Score 2= Vascular narrowing of 26 to 50% luminal area by fibrointimal thickening and Score 3= Vascular narrowing of more than 50% luminal area by fibrointimal thickening.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 33.3 | 36 |
| Banff Lesion Score 1 | 40.7 | 41.2 |
| Banff Lesion Score 2 | 22 | 17.6 |
| Banff Lesion Score 3 | 2.4 | 2.2 |
| Not able to score | 1.6 | 2.9 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No periodic acid-Schiff (PAS)-positive hyaline arteriolar thickening, Score 1= Mild to moderate PAS-positive hyaline thickening in at least 1 arteriole, Score 2= Moderate to severe PAS-positive hyaline thickening in more than 1 arteriole and Score 3= Severe PAS-positive hyaline thickening in many arterioles.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 91.1 | 86.8 |
| Banff Lesion Score 1 | 4.1 | 5.9 |
| Banff Lesion Score 2 | 4.1 | 3.7 |
| Banff Lesion Score 3 | 0 | 2.2 |
| Not able to score | 0.8 | 1.5 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= Maximum number of leukocytes \<3, Score 1= At least 1 leukocyte cell in ≥10% of cortical PTCs with 3-4 leukocytes in most severely involved PTC, Score 2= At least 1 leukocyte in ≥10% of cortical PTC with 5-10 leukocytes in most severely involved PTC and Score 3= At least 1 leukocyte in ≥10% of cortical PTC with \>10 leukocytes in most severely involved PTC.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 91.1 | 90.4 |
| Banff Lesion Score 1 | 3.3 | 5.1 |
| Banff Lesion Score 2 | 4.9 | 2.9 |
| Banff Lesion Score 3 | 0 | 0.7 |
| Not able to score | 0.8 | 0.7 |
Central pathology reading was performed as per the 2007 Update to the Banff '97 classification. Banff Lesion Scores assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies, focusing primarily but not exclusively on the diagnostic features seen in rejection. \[Roufosse C et. al 2018\]. Here, Score 0= No more than mild mesangial matrix increase in any glomerulus, Score 1= At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli, Score 2= At least moderate mesangial matrix increase in 26% to 50% of nonsclerotic glomeruli and Score 3= At least moderate mesangial matrix increase in \>50% of nonsclerotic glomeruli.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Banff Lesion Score 0 | 87.8 | 91.2 |
| Banff Lesion Score 1 | 8.9 | 6.6 |
| Banff Lesion Score 2 | 2.4 | 0.7 |
| Banff Lesion Score 3 | 0 | 0 |
| Not able to score | 0.8 | 1.5 |
DSA was considered as a categorical (binary) variable with positivity determined at a threshold criteria approaching MFI=1000 at any time during the study.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of DSA | NA ± NA | NA ± NA |
Time to first occurrence of HLA-DQ DSA was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of HLA-DQ DSA | NA ± NA | NA ± NA |
Time to first occurrence of C1q-binding DSA was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of C1q-binding DSA | NA ± NA | NA ± NA |
Time to first occurrence of DSA IgG3 isotype was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of DSA IgG3 Isotype | NA ± NA | NA ± NA |
Time to first occurrence of IA was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of IA | NA ± NA | NA ± NA |
Time to first occurrence of TG on biopsy was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of TG on Biopsy | NA ± NA | NA ± NA |
Time to occurrence of death was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to Occurrence of Death | NA (NA to NA) | NA (NA to NA) |
Time to first occurrence of local BPAR was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Local BPAR | NA ± NA | NA ± NA |
Time to first occurrence of acute forms of ABMR was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Acute Forms of ABMR | NA ± NA | NA ± NA |
Time to first occurrence of chronic forms of ABMR was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Chronic Forms of ABMR | NA ± NA | NA ± NA |
Time to first occurrence of acute TCMR was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Acute TCMR | NA ± NA | NA ± NA |
Time to first occurrence of chronic TCMR was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Chronic TCMR | NA ± NA | NA ± NA |
Time to first occurrence of borderline changes was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of Borderline Changes | NA ± NA | NA ± NA |
Time to first occurrence of IFTA was reported.
| days | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Time to First Occurrence of IFTA | NA ± NA | NA ± NA |
A TEAE was defined as an Adverse Event (AE) observed on or after the day of starting the administration of the test drug/comparative drug.
| percentage of participants | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| TEAEs | 99.7 | 98.6 |
| TEAEs related to study treatment | 77.8 | 70.7 |
| TESAEs | 56.6 | 47.4 |
| TESAEs related to study treatment | 27.4 | 23.7 |
| TEAEs causing discontinuation of study treatment | 16.3 | 13.9 |
| TEAEs leading to death | 0.7 | 0.7 |
Collected over From first dose of study drug up to 7 days after last dose of study drug (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus, Extended Release (Astagraf XL®) Once Daily | 2/288 (0.7%) | 163/288 (56.6%) | 285/288 (99%) |
| Tacrolimus, Immediate Release BID | 2/287 (0.7%) | 136/287 (47.4%) | 278/287 (96.9%) |
| Event | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 26/288 | 31/287 |
| Urinary tract infectionInfections and infestations | 16/288 | 11/287 |
| HyperkalaemiaMetabolism and nutrition disorders | 15/288 | 5/287 |
| Kidney transplant rejectionImmune system disorders | 12/288 | 14/287 |
| DiarrhoeaGastrointestinal disorders | 7/288 | 11/287 |
| SepsisInfections and infestations | 7/288 | 10/287 |
| PneumoniaInfections and infestations | 10/288 | 7/287 |
| Blood creatinine increasedInvestigations | 10/288 | 8/287 |
| PyrexiaGeneral disorders | 9/288 | 8/287 |
| VomitingGastrointestinal disorders | 4/288 | 7/287 |
| Event | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 128/288 | 115/287 |
| HypomagnesaemiaMetabolism and nutrition disorders | 124/288 | 124/287 |
| HypophosphataemiaMetabolism and nutrition disorders | 122/288 | 122/287 |
| NauseaGastrointestinal disorders | 101/288 | 104/287 |
| ConstipationGastrointestinal disorders | 90/288 | 100/287 |
| TremorNervous system disorders | 94/288 | 84/287 |
| Procedural painInjury, poisoning and procedural complications | 55/288 | 91/287 |
| HyperkalaemiaMetabolism and nutrition disorders | 81/288 | 79/287 |
| LeukopeniaBlood and lymphatic system disorders | 66/288 | 58/287 |
| VomitingGastrointestinal disorders | 41/288 | 61/287 |
The randomized set consisted of all participants who were randomized to receive the study drug (Astagraf XL or BID tacrolimus).
| Age, Continuous(Years) | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID | Total |
|---|---|---|---|
| Mean | 49 ± 11.7 | 48.5 ± 11.6 | 48.8 ± 11.7 |
| Sex: Female, Male(Participants) | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID | Total |
|---|---|---|---|
| Female | 111 | 91 | 202 |
| Male | 189 | 208 | 397 |
| Ethnicity (NIH/OMB)(Participants) | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 34 | 66 |
| Not Hispanic or Latino | 268 | 265 | 533 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tacrolimus, Extended Release (Astagraf XL®) Once Daily | Tacrolimus, Immediate Release BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 5 |
| Asian | 10 | 14 | 24 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 58 | 67 | 125 |
| White | 212 | 200 | 412 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 14 | 16 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Sep 2016 to primary completion in Jun 2019, 33 months.
Results were first posted in Jun 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus
Astellas Pharma Global Development, Inc. →